- Investing Ideas
- Australian Pharmaceuticals & Biotech High Return On Equity, Low Debt
Australian Pharmaceuticals & Biotech High Return On Equity, Low Debt
Results
2
0 new
Stocks with a return on equity of over 30% and a debt to equity ratio below 1.
2 companies
BLS Pharmaceuticals
Market Cap: AU$223.1m
Manufactures and distributes therapeutic goods, and health and wellness products in Australia, the United States, the United Kingdom, Czech Republic, and Japan.
BLS
AU$0.97
7D
4.3%
1Y
115.6%
Cann Group
Market Cap: AU$6.6m
Engages in the breeding, cultivation, manufacture, and sale of medicinal cannabis in Australia and Europe.
CAN
AU$0.004
7D
0%
1Y
-75.0%